Essilor® Stellest® Lenses Multicentre European Study (SLOMES)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-22

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety, acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in slowing myopia progression in European children and adolescents. Participants will receive Essilor® Stellest® at inclusion visit and will be asked for a full time wear (\>12 hours daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic autorefraction from baseline to 24 months compared to expected change based on axial length and refraction centile positions at baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stellest Lens Wear in Adult Progressing Myopes

NCT06520124

Myopia, Progressive

RECRUITING NA

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (CSL)

NCT05724186

Myopia

COMPLETED NA

Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses

NCT07340931

Myopia

NOT_YET_RECRUITING

Stellest Lenses and Low-concentration Atropine Myopia Control Among Children

NCT06344429

Myopia

RECRUITING NA

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression

NCT05331378

Myopia, Progressive Myopia

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial design is a multicentre, European, prospective, interventional study with single group assignment. The investigational medical device Essilor® Stellest® is a CE marked, myopia control spectacle lens. The trial period for all participants is 24 months. The recruiting period is 6 to 9 months depending on countries / sites for a total of 150 participants (50 in Ireland, 75 in France and 25 in The Netherlands).

The secondary objectives are:

* To evaluate the acceptability of Essilor® Stellest® spectacle lenses in slowing myopia progression.
* To evaluate the quality-of-life implications for children and adolescents.
* To evaluate the safety of Essilor® Stellest® spectacle lenses in slowing myopia progression.
* To evaluate the effect of Essilor® Stellest® spectacle lenses on choroidal thickness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

multicentre, European, prospective

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Essilor® Stellest® spectacle lenses

patients will be asked to wear Essilor® Stellest® spectacle lenses for a full time wear (\>12 hours daily) for 24 months

Group Type OTHER

Essilor® Stellest® spectacle lenses

Intervention Type DEVICE

patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Essilor® Stellest® spectacle lenses

patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \- Myopia as determined by cycloplegic autorefraction as follows:

* Each meridian SER of plano to - 8;00 D in each eye
* Astigmatism \< 2.50 D
* Anisometropia ≤ 1.50 D
2. \- Monocular corrected VA of at least 0.2 LogMAR in both eyes
3. \- Age: 6 - 16 years old, inclusive at the time of inclusion
4. \- Ability to understand treatment and give valid assent
5. \- Ability to comply with the protocol to get reliable study measurements

Exclusion Criteria

1. \- Concomitant or previous therapies for myopia
2. \- Eye diseases/conditions:

* Strabismus by cover test at near or distance
* Any ocular disease that would influence refractive development e.g. retinal disease, cataract, ptosis
* Any systemic or neurodevelopmental conditions that may influence refractive development
3. \- Use of ocular or systemic medication which may affect myopia progression or visual acuity through known effects on retina, accommodation, or significant elevation of intraocular pressure
4. \- Participation in another study which may influence vision or interfere with study assessments
5. \- Myopia onset before 5 years of age
6. \- Contact lens wearers

Minimum Eligible Age

6 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No